The global bioimpedance spectroscopy market was valued at USD 469.8 Million in 2022 and is expected to reach USD 1.4 Billion by 2033. The single-frequency bioimpedance spectroscopy segment with a market share of around 73.0% in 2022, has topped the global market within the product category and is expected to grow at a CAGR of close to 10.4% over the forecast period (2023 to 2033).
Market Outlook:
| Data Points | Market Insights |
|---|---|
| Market Value 2022 | USD 469.8 Million |
| Market Value 2023 | USD 512.5 Million |
| Market Value 2033 | USD 1.4 Billion |
| CAGR 2023 to 2033 | 10.4% |
| Market Share of Top 5 Countries | 54.6% |
| Key Market Players | Tanita Corporation, Akern, Biodynamics Corporation, Bioparhom, Biotekna, Bodystat Ltd, Charder Electronic Co. Ltd, Evolt 360, Fook Tin Group Holding Ltd, InBody Co. Ltd, Lumsail Industrial Inc., Maltron International, Omron Corporation, RJL Systems, Seca GmbH & Co. KG, SELVAS Healthcare Inc., Sino-Hero, Withings, ImpediMed Ltd. And Samsung. |
The electrical characteristics of biological tissues may be measured and analyzed using bioimpedance spectroscopy (BIS). A tiny current of electricity is sent across the human body while the resultant voltage is measured to assess several physiological characteristics. BIS can give useful information regarding the composition of the body, fluid distribution, cell membrane integrity, and tissue health by analysing impedance readings at numerous frequencies.
In healthcare and scientific contexts, BIS is frequently used for applications such as measuring hydration status, tracking variations in body composition, measuring tissue health in disorders such as lymphedema, and directing treatment decisions. It provides a rapid, safe, and cost-effective approach to gaining useful information regarding an individual's state of health.
Overall, BIS is important for measuring and monitoring numerous aspects of human health, enabling personalized treatment methods, and optimizing patient care. BIS has proved useful for monitoring blood fluid variations, especially in post-surgical and HIV-infected patients. BIS, as a label-free, non-destructive, and simple-to-implement technology, has emerged as a potential experimental strategy in biological and medical applications such as biosensing technologies and disease diagnostics, including cancer and viral detection.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global market recorded a historic CAGR of 8.3% in the last 5 years from 2017 to 2022. The market value for bioimpedance spectroscopy (BIS) was around 75.3% of the overall USD 624.0 Million of the global body composition analyzers market in 2022.
The increasing prevalence of obesity can have a significant impact on this market. According to the data published by “World Obesity Atlas 2022”, it is estimated worldwide, out of 8 billion people, about 2.3 billion children and adults are estimated to be classified as overweight or obese. This points to the fact that obesity is a significant public health concern and accurate assessment of body composition is crucial for managing and treating obesity. Hence, the demand for body mass analyzers is anticipated to rise along with the number of obese people.
The increasing prevalence of obesity would likely lead to higher demand for body composition analysis tools like BIS. Other than this, increased healthcare spending on a global level may result in more acceptance and use of such technology. These parameters reflect a steady growth of this market in the coming years.
As healthcare professionals and patients are becoming more aware of the benefits of bioimpedance spectroscopy, there is an opportunity for increased use of this technique. BIS can provide valuable insights into a person's body composition, including muscle mass, fat mass, and fluid distribution.
With the rising global prevalence of obesity and associated health concerns, there is a growing demand for accurate and non-invasive body composition assessment tools. BIS manufacturers can capitalize on this opportunity by developing advanced BIS devices that offer precise measurements and user-friendly interfaces.
This technology can help with the early identification, monitoring, and management of various disorders, resulting in better patient outcomes. According to the findings reported in the European Journal of Breast Health in May 2022, bioimpedance spectroscopy (BIS) seems helpful for earlier diagnosis of lymphedema associated with breast cancer. This presents lucrative opportunities for this market because the prevalence of breast cancer is quite high.
Principal Consultant
While bioimpedance spectroscopy has been shown to be effective in some areas, such as body composition analysis and fluid status evaluation, its applicability in other fields is still in the early stages. Bioimpedance spectroscopy data may be challenging to assess and integrate into clinical decision-making.
BIS generates a significant amount of data and effectively interpreting and integrating this data into clinical decision-making processes can be a challenge. Healthcare providers may require training and support to leverage the full potential of BIS data for patient management. This would hamper the growth of the market in the forecasted period.
The lack of awareness and familiarity among healthcare professionals is a significant factor restraining the demand for bioimpedance spectroscopy (BIS). Limited knowledge about the capabilities and benefits of BIS hampers its adoption in clinical practice. Healthcare providers may be hesitant to invest in a technology they are not familiar with, leading to slower market growth.
The USA accounted for 89.5% market value share of the North American market in the year 2022. The USA healthcare industry fosters collaborations and partnerships between medical device companies, research institutions, and healthcare providers. These collaborations help drive the development, validation, and adoption of BIS technologies in the market.
USA has a high prevalence of chronic diseases. According to data published by CDC in 2022, six in ten Americans live with at least one chronic disease, like heart disease and stroke, cancer, or diabetes. BIS offers valuable insights into the assessment and monitoring of fluid status, body composition, and cellular health, making it relevant and in-demand for managing these chronic conditions.
Germany expenditure on bioimpedance spectroscopic diagnosis in 2022 was USD 31.4 Million. Germany has a highly competent and well-trained workforce in healthcare, including physicians, researchers, and technicians. These experts are skilled in the use and interpretation of bioimpedance spectroscopy data, allowing the technique to be widely adopted and applied in clinical practice and research.
According to data published Journal of Health Monitoring in 2022, 53.5% of people in Germany are overweight, with 19.0% of adults in Germany having obesity. Further studies showed low education group exhibited higher prevalence of obesity than the high education group. This imbalance is critical in promoting the bioimpedance spectroscopy market in Germany.
In 2022, China held a dominant share of 38.7% in the East Asia. China is a predominant center for medical research and development. This increased spending provides opportunities for the adoption of advanced medical technologies, including BIS devices, in both clinical and non-clinical settings.
China has experienced a significant increase in obesity rates over the past few decades. Rapid urbanization, changing dietary patterns, sedentary lifestyles, and other socioeconomic factors have contributed to the rise in obesity. According to SHS Web of Conferences 2023, 49.1% of Chinese women aged 18-24 did not have a college education or higher degree. The prevalence of obesity was higher in Chinese socio-demographic groupings, creating an enormous demand for bioimpedance spectroscopy for obesity detection.
BIS technology can be utilized in various healthcare settings in China. This includes clinical settings for obesity management, monitoring fluid balance in patients with chronic conditions, and assessing body composition for personalized treatment plans.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Single frequency bioimpedance spectroscopy segment represented around USD 342.7 Million market value in 2022.
There is no loss of information while measuring tissue hydration during fluid evacuation with HD using a single-frequency 50 kHz-impedance vector displacement. Bioimpedance analysis (BIA) via a single frequency current i.e. 50 kHz provides the most accurate insights at the tissue level because it maximizes the signal-to-noise ratio and minimises both frequency dependent errors and variability of electric flow paths. Single frequency bioimpedance spectroscopy is chosen over multi-frequency bioimpedance spectroscopy because of its high degree of accuracy.
By modality, the hand-held BIA accounted for a prominent share in the global bioimpedance spectroscopy market, with a revenue share of 56.7% in 2022. Hand-held BIA is a particularly convenient BIA approach and has been used for more than a decade.
In accordance with a study published in the Journal of Nutrients 2016, body fat percentage calculation using the hand-held BIA model in the standing posture was substantially linked with dual-energy X-ray absorptiometry-estimated body fat.
In addition, the precision of the hand-to-hand BIA model findings was considerably higher than that of the hand-to-foot BIA model, indicating that the hand-to-hand BIA model in the standing position is practical for body composition evaluation. Therefore, the hand-held BIA segment dominates over other types of modalities in this market.
The hospitals have a considerable presence in the bioimpedance spectroscopy market, accounting for 47.8% of the market in 2022 and exhibiting a high CAGR of 9.5%. Hospitals provide comprehensive care facilities where patients receive multidisciplinary care.
BIS technology can be integrated into the overall healthcare framework of hospitals, complementing other diagnostic modalities and treatments. The availability of BIS devices in hospitals enhances the range of tools and techniques healthcare professionals can utilize to deliver comprehensive patient care.
Collaborations and partnerships among healthcare providers, research institutions, and technology businesses can encourage innovation and hasten bioimpedance spectroscopy adoption. Collaboration in research, development, and commercialization can lead to market expansion and the creation of new applications. Numerous big tech giants and firms compete in the field of bioimpedance spectroscopy.
In comparison to other firms, Samsung has earned a technological advantage in BIS application, and the additional feature in its newly issued watch has helped develop an appealing feature in the heart of health-conscious consumers.
ImpediMed Ltd. developed digital health screening platform named SOZO for detection of lymphoedema. New guidelines were released by National Comprehensive Cancer Network (NCCN) for cancer care, cancer patients at risk of lymphoedema need to be screened at frequent intervals to identify early indications using symptom evaluation, clinical examinations, and BIS.
With technological advances in the medical sector bioimpedance spectroscopy will be useful in diagnosing breast cancer and measuring obesity, both of which are on the rise in the current time.
Similarly, recent developments related to the company’s manufacturing the bioimpedance spectroscopy have been tracked by the team at Future Market Insights, which are available in the full report.
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2017 to 2022 |
| Market Analysis | USD Million for Value, Units for Volume |
| Key Regions Covered | North America, Latin America, Europe, East Asia, South Asia, Oceania, Middle East and Africa (MEA) |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, United Kingdom, Germany, Italy, France, Spain, Russia BENELUX, India, Indonesia, Thailand, Malaysia, China, Japan, South Korea, Australia, New Zealand, GCC Countries, Türkiye, Northern Africa and South Africa. |
| Key Market Segments Covered | Product, Modality, End User, and Region |
| Key Companies Profiled | Tanita Corporation; Akern; Biodynamics Corporation; Bioparhom; Biotekna; Bodystat Ltd; Charder Electronic Co. Ltd; Evolt 360; Fook Tin Group Holding Ltd; InBody Co. Ltd; Lumsail Industrial Inc.; Maltron International; Omron Corporation; RJL Systems; Seca GmbH & Co. KG; SELVAS Healthcare Inc.; Sino-Hero; Withings; ImpediMed Ltd.; Samsung |
| Report Coverage | Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
| Pricing | Available upon Request |
The market is projected to generate USD 512.5 million in sales by 2023.
The global market is set to be worth USD 1.4 billion by 2033.
The market is estimated to advance at a 10.4% CAGR through 2033.
Opportunities for bioimpedance spectroscopy manufacturers include customized medicine, research adoption, and wearable health technology.
In terms of market value, the United States accounted for 89.5% of the North American market.
China controlled the East Asia market with a 38.7% share.
1. Executive Summary 2. Market Overview 3. Key Market Trends 4. Value-Added Insights 5. Market Background 6. Global Market Demand Volume (Units) Analysis 2017 to 2022 and Forecast, 2023 to 2033 7. Global Market - Pricing Analysis 8. Global Market Demand (in Value or Size in US$ Million) Analysis 2017 to 2022 and Forecast, 2023 to 2033 9. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Product 9.1. Single Frequency 9.2. Multiple Frequency 10. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Modality 10.1. Hand-held BIA 10.2. Hand-to-Foot BIA 10.3. Leg-to-Leg BIA 11. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By End User 11.1. Hospitals 11.2. Specialty Clinics 11.3. Ambulatory Surgical Centers 11.4. Rehabilitation Centers 12. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Region 12.1. North America 12.2. Latin America 12.3. Europe 12.4. South Asia 12.5. East Asia 12.6. Oceania 12.7. Middle East and Africa (MEA) 13. North America Market Analysis 2017 to 2022 and Forecast 2023 to 2033 14. Latin America Market Analysis 2017 to 2022 and Forecast 2023 to 2033 15. Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033 16. South Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033 17. East Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033 18. Oceania Market Analysis 2017 to 2022 and Forecast 2023 to 2033 19. Middle East and Africa Market Analysis 2017 to 2022 and Forecast 2023 to 2033 20. Market Structure Analysis 21. Competition Analysis 21.1. Tanita Corporation 21.2. Akern, Biodynamics Corporation 21.3. Bioparhom, Biotekna 21.4. Bodystat Ltd 21.5. Charder Electronic Co. Ltd 21.6. Evolt 360 21.7. Fook Tin Group Holding Ltd 21.8. InBody Co. Ltd 21.9. Lumsail Industrial Inc. 21.10. Maltron International 21.11. Omron Corporation 21.12. RJL Systems 21.13. Seca GmbH & Co. KG 21.14. SELVAS Healthcare Inc. 21.15. Sino-Hero 21.16. Withings 21.17. ImpediMed Ltd. 21.18. Samsung 22. Assumptions and Acronyms Used 23. Research Methodology
Explore Healthcare Insights
View Reports
Bioimpedance Spectroscopy Market
